Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 18/20 | 0.67 |
| ▸ | GSK3A | P49840 | 6/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6071654 | 1.00 | GSK3B (0.67) | GSK3BGSK3AADORA1MAPK14MEN1 | |
| SCHEMBL6071711 | 0.88 | GSK3B (0.60) | GSK3BGSK3AADORA1 | |
| SCHEMBL6071701 | 0.88 | GSK3B (0.60) | GSK3BGSK3AADORA1 | |
| SCHEMBL6071990 | 0.85 | GSK3B (0.75) | GSK3BGSK3AADORA1MAPK14 | |
| SCHEMBL6071982 | 0.85 | GSK3B (0.75) | GSK3BGSK3AADORA1MAPK14 | |
| SCHEMBL6207362 | 0.84 | GSK3B (0.57) | GSK3BGSK3AADORA1MEN1MAPT | |
| SCHEMBL8344002 | 0.83 | GSK3B (0.74) | GSK3BGSK3AADORA1MEN1MAPT | |
| SCHEMBL6363291 | 0.82 | GSK3B (0.65) | GSK3BGSK3AADORA1MEN1MAPT | |
| SCHEMBL6363280 | 0.82 | GSK3B (0.65) | GSK3BGSK3AADORA1MEN1MAPT | |
| SCHEMBL8345215 | 0.81 | GSK3B (0.81) | GSK3BGSK3AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060167020-A1 | Pyrazolopyrimidines as kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167020-A1 | Pyrazolopyrimidines as kinase inhibitors | MAP3K12, MAP3K5, MAP3K2 | GSK3B 591/4885GSK3A 662/4885ADORA1 4148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.